HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Provenzano R, Fishbane S, Coyne DW, et al.

Roxadustat Treatment of Anemia in Non-Dialysis-Dependent CKD Is Not Influenced by Iron Status

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:1A 2020

BACKGROUND

Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor for anemia in CKD, improves iron absorption and bioavailability. This analysis of Phase 3 studies explored the efficacy of roxadustat in pts with non-dialysis-dependent (NDD) CKD with iron repletion or depletion at baseline.

METHODS

Data from 3 completed randomized Phase 3 studies in NDD-CKD pts were analyzed individually and in the pooled population by iron status. Pts were randomized to roxadustat or placebo for up to 4 years. Baseline (BL) hemoglobin (Hb) and change from BL (CFB) were summarized overall and in pts with iron repletion or iron depletion. Iron repletion was defined as ferritin ≥100 μg/L and transferrin saturation (TSAT) ≥20%; the remainder were defined as iron depleted. Oral iron was allowed on study and IV iron was allowed as rescue.

RESULTS

Across studies, 2391 and 1886 pts with NDD-CKD were treated with roxadustat and placebo, respectively. Mean (SD) BL Hb was 9.10 (0.74) g/dL (roxadustat) and 9.10 (0.73) g/dL (placebo). At BL, 1433 (60%) pts were iron replete for roxadustat and 1127 (60%) pts were iron replete for placebo. Mean CFB in Hb with roxadustat was summarized by study and iron status (Table 1). Hb CFB was similar in iron-replete and -depleted patients receiving roxadustat. Roxadustat dose and iron use in subgroups will be explored.

CONCLUSION

Roxadustat corrected and maintained Hb in patients with NDD-CKD and anemia regardless of iron status at baseline.

CHANGE FROM BASELINE IN HB OVERALL AND BY IRON STATUS WITH ROXADUSTAT TREATMENT ACROSS NDD STUDIES OVER WEEKS 28 TO 52 REGARDLESS OF RESCUE THERAPY
StudyN in analysisMean (SD) baseline Hb for study (g/dL)Adjusted LS mean Change from baseline in Hb
001
(OLYMPUS)
Overall = 13849.11 (0.73)1.75 (0.03)†
Iron-replete = 7821.71 (0.04)†
Iron-depleted = 5521.76 (0.05)†
060
(ANDES)
Overall = 6169.10 (0.75)2.02 (0.04)†
Iron-replete = 3661.98 (0.05)†
Iron-depleted = 2412.10 (0.07)†
608
(ALPS)
Overall = 3919.08 (0.76)1.99 (1.82, 2.16)§
Iron-replete = 2041.97 (1.74, 2.20)§
Iron-depleted = 1871.99 (1.69, 2.29)§
PooledOverall = 23919.10 (0.74)1.94 (0.02)†
Iron-replete = 14331.94 (0.03)†
Iron-depleted = 9561.94 (0.03)†
†Least squares mean change from baseline to average during Weeks 28–52 (± standard error) in the intention to treat population for overall results; least squares mean change from baseline to average during Weeks 28–36 (± standard error) in the FAS population for baseline iron subgroup results.
§Least squares mean change from baseline to average Hb during Weeks 28 -52 (95% confidence interval) in the all randomized population.
Least squares mean was derived using the multiple imputation strategy by combining the results of the ANCOVA model with other covariates.
For 001, iron replete was defined as ferritin >100 μg/L and transferrin saturation >20%.
For 001, iron depleted was defined as ferritin <100 μg/L and <20%.
Hb, hemoglobin; LS, least squares; NDD, non-dialysis dependent; standard deviation, SD.

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.